Volume 8, Issue 3 (12-2009)
JRUMS 2009, 8(3): 185-192 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Iranmanesh F, Zia Sheikholeslami N. Therapeutic Effects of Beta- Interferons in Patients with Multiple Sclerosis. JRUMS 2009; 8 (3) :185-192
URL: http://journal.rums.ac.ir/article-1-5354-en.html
URL: http://journal.rums.ac.ir/article-1-5354-en.html
Abstract: (1488 Views)
Background and Objectives: B-Interferons have been reported as effective medicine in the treatment of Multiple Sclerosis (MS), but due to their cost and side effects, the duration of therapy is controversial. The current study aimed to reveal the rate of recurrence according to the duration of medication among the patients receiving B- Interferons in a 2 year period in Rafsanjan city.
Materials and Methods: In this cohort study, patients who had relapsing-remiting MS for at least 2 years and had been receiving B-Interferon for at least 3 months were followed. The patients were given a questionaire containing their demographic information, recurrence rate and duration of treatment with B- Interferon.
Results: Sixty three point six percent had no exacerbation in the group receiving medication for 3-6 months, while 38.1% in the 6 months-1 year group, and 41.7% in the 1 year group had no exacerbation. There was no significant relationship between the duration of receiving medicaton and the number of recurrence rate. Recurrence rate in the first and second group [<12 months therapy] was 0.46% and in the third group [>12 months therapy] was 0.35%.
Conclusion: The results showed no significant relationship between recurrence rate and the duration of B- Interferon therapy. Longer period of treatment is recommended to asses the therapeutic effects of beta-interferon.
Key words: Multiple Sclerosis, B-Interferon, Recurrence
Funding: This Research was funded by Rafsanjan University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethical Committee of Rafsanjan University of Medical Sciences approved the study.
Materials and Methods: In this cohort study, patients who had relapsing-remiting MS for at least 2 years and had been receiving B-Interferon for at least 3 months were followed. The patients were given a questionaire containing their demographic information, recurrence rate and duration of treatment with B- Interferon.
Results: Sixty three point six percent had no exacerbation in the group receiving medication for 3-6 months, while 38.1% in the 6 months-1 year group, and 41.7% in the 1 year group had no exacerbation. There was no significant relationship between the duration of receiving medicaton and the number of recurrence rate. Recurrence rate in the first and second group [<12 months therapy] was 0.46% and in the third group [>12 months therapy] was 0.35%.
Conclusion: The results showed no significant relationship between recurrence rate and the duration of B- Interferon therapy. Longer period of treatment is recommended to asses the therapeutic effects of beta-interferon.
Key words: Multiple Sclerosis, B-Interferon, Recurrence
Funding: This Research was funded by Rafsanjan University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethical Committee of Rafsanjan University of Medical Sciences approved the study.
Type of Study: Research |
Subject:
Neurology
Received: 2020/05/16 | Accepted: 2020/05/16 | Published: 2020/05/16
Received: 2020/05/16 | Accepted: 2020/05/16 | Published: 2020/05/16
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
